ENTA ENANTA PHARMACEUTICALS INCcompanySEC Filings & Insider Trading Activity 2026
Latest ENANTA PHARMACEUTICALS INC (ENTA) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on November 19, 2025, a 10-Q quarterly report filed on February 11, 2026, an 8-K current report filed on March 26, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ENANTA PHARMACEUTICALS INC (ENTA) (SEC CIK 1177648), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 5.07: Submission of Matters to a Vote of Security Holders
- • Directors re-elected: Bruce Carter (Ph.D.) with 81.4% support; Jay Luly (Ph.D.) with 99.2% support — notably high vote against Carter
- • Equity plan amended to add 1,600,000 shares to 2019 Equity Incentive Plan, approved 78% For vs 21.6% Against — moderate shareholder resistance signals dilution concern
Recent 8-K FilingsCurrent Reports
AI-powered analysis of ENANTA PHARMACEUTICALS INC (ENTA) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 26, 2026 | — | — | — |
8-K | Mar 12, 2026 | — | Analysis | — |
10-Q | Feb 11, 2026 | Dec 31, 2025 | — | |
8-K | Feb 9, 2026 | — | — | |
10-K | Nov 19, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 13, 2025 | Jun 30, 2025 | — | |
10-Q | May 14, 2025 | Mar 31, 2025 | — | |
10-Q | Feb 12, 2025 | Dec 31, 2024 | — | |
10-K | Nov 27, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 7, 2024 | Jun 30, 2024 | — | |
10-Q | May 8, 2024 | Mar 31, 2024 | — | |
10-Q | Feb 8, 2024 | Dec 31, 2023 | — | |
10-K | Nov 22, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 8, 2023 | Jun 30, 2023 | — | |
10-Q | May 9, 2023 | Mar 31, 2023 | — | |
10-Q | Feb 8, 2023 | Dec 31, 2022 | — | |
10-K | Nov 23, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 8, 2022 | Jun 30, 2022 | — | |
10-Q | May 9, 2022 | Mar 31, 2022 | — | |
10-Q | Feb 10, 2022 | Dec 31, 2021 | — | |
10-K | Nov 24, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 9, 2021 | Jun 30, 2021 | — | |
10-Q | May 10, 2021 | Mar 31, 2021 | — | |
10-Q | Feb 9, 2021 | Dec 31, 2020 | — | |
10-K | Nov 25, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest ENTA SEC filings in 2026?
ENANTA PHARMACEUTICALS INC (ENTA) has filed a 10-K annual report on November 19, 2025, a 10-Q quarterly report on February 11, 2026, an 8-K current report on March 26, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ENTA file its most recent 10-K annual report?
ENANTA PHARMACEUTICALS INC (ENTA) filed its most recent 10-K annual report on November 19, 2025. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ENTA 10-Q quarterly reports?
ENANTA PHARMACEUTICALS INC (ENTA)'s most recent 10-Q quarterly report was filed on February 11, 2026. SignalX displays every ENTA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ENTA filed recently?
ENANTA PHARMACEUTICALS INC (ENTA)'s most recent 8-K was filed on March 26, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ENTA insider trading activity (Form 4)?
SignalX aggregates every ENTA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ENTA file with the SEC?
ENANTA PHARMACEUTICALS INC (ENTA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ENTA filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ENANTA PHARMACEUTICALS INC (ENTA).
What is ENTA's SEC CIK number?
ENANTA PHARMACEUTICALS INC (ENTA)'s SEC CIK (Central Index Key) number is 1177648. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1177648 to look up all ENTA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ENTA return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from ENANTA PHARMACEUTICALS INC (ENTA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of ENANTA PHARMACEUTICALS INC SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 55+ filings.